AstraZeneca Targets Actavis In Latest Nexium IP Suit
AstraZeneca AB launched a suit Tuesday in New Jersey federal court accusing drugmaker Actavis Inc. of infringing five of its patents for the heartburn drug Nexium by seeking federal approval to...To view the full article, register now.
Already a subscriber? Click here to view full article